Impact of Preoperative Tumor Size on Prognosis of Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinomas
© 2023. Society of Surgical Oncology..
BACKGROUND: Tumor size (TS) is a well-established prognostic factor of pancreatic ductal adenocarcinoma (PDAC). However, whether a uniform treatment strategy can be applied for all resectable PDACs (R-PDACs) and borderline resectable PDACs (BR-PDACs), regardless of TS, remains unclear. This study aimed to investigate the impact of preoperative TS on surgical outcomes of patients with R-PDACs and BR-PDACs.
METHODS: Chart data from three institutions were reviewed to select patients who underwent pancreatectomy for R-PDACs and BR-PDACs between January 2006 and December 2020. The patients were divided into TSsmall and TSlarge groups according to a TS cutoff value determined for each of R- and BR-PDAC using the minimum P value approach for the risk of R1 resection.
RESULTS: TS of 35 mm and 24 mm was the best cutoff value in R-PDAC and BR-PDAC, respectively. The R1 rate was higher in the TSlarge than TSsmall group, in both R- (n = 35, 37% versus n = 294, 19%; P = 0.011) and BR-PDAC (n = 89, 37% versus n = 27, 15%; P = 0.030). Overall survival was significantly better in the TSsmall than TSlarge group in R-PDAC (38.2 versus 12.1 months; P < 0.001), but comparable between the two groups in BR-DPAC (21.2 versus 22.7 months; P = 0.363). Multivariate analysis revealed TS > 35 mm as an independent predictor of worse survival in patients with R-PDAC.
CONCLUSION: Larger TS was associated with a higher R1 rate and is a worse prognostic factor in patients with R-PDAC.
| Errataetall: |
CommentIn: Ann Surg Oncol. 2023 Dec;30(13):8644-8645. - PMID 37689609 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:30 |
|---|---|
| Enthalten in: |
Annals of surgical oncology - 30(2023), 13 vom: 01. Dez., Seite 8621-8630 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Miyata, Yoichi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 08.11.2023 Date Revised 13.12.2023 published: Print-Electronic CommentIn: Ann Surg Oncol. 2023 Dec;30(13):8644-8645. - PMID 37689609 Citation Status MEDLINE |
|---|
| doi: |
10.1245/s10434-023-14219-3 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36156015X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36156015X | ||
| 003 | DE-627 | ||
| 005 | 20231227131530.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1245/s10434-023-14219-3 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1225.xml |
| 035 | |a (DE-627)NLM36156015X | ||
| 035 | |a (NLM)37658273 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Miyata, Yoichi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Impact of Preoperative Tumor Size on Prognosis of Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinomas |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.11.2023 | ||
| 500 | |a Date Revised 13.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Ann Surg Oncol. 2023 Dec;30(13):8644-8645. - PMID 37689609 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. Society of Surgical Oncology. | ||
| 520 | |a BACKGROUND: Tumor size (TS) is a well-established prognostic factor of pancreatic ductal adenocarcinoma (PDAC). However, whether a uniform treatment strategy can be applied for all resectable PDACs (R-PDACs) and borderline resectable PDACs (BR-PDACs), regardless of TS, remains unclear. This study aimed to investigate the impact of preoperative TS on surgical outcomes of patients with R-PDACs and BR-PDACs | ||
| 520 | |a METHODS: Chart data from three institutions were reviewed to select patients who underwent pancreatectomy for R-PDACs and BR-PDACs between January 2006 and December 2020. The patients were divided into TSsmall and TSlarge groups according to a TS cutoff value determined for each of R- and BR-PDAC using the minimum P value approach for the risk of R1 resection | ||
| 520 | |a RESULTS: TS of 35 mm and 24 mm was the best cutoff value in R-PDAC and BR-PDAC, respectively. The R1 rate was higher in the TSlarge than TSsmall group, in both R- (n = 35, 37% versus n = 294, 19%; P = 0.011) and BR-PDAC (n = 89, 37% versus n = 27, 15%; P = 0.030). Overall survival was significantly better in the TSsmall than TSlarge group in R-PDAC (38.2 versus 12.1 months; P < 0.001), but comparable between the two groups in BR-DPAC (21.2 versus 22.7 months; P = 0.363). Multivariate analysis revealed TS > 35 mm as an independent predictor of worse survival in patients with R-PDAC | ||
| 520 | |a CONCLUSION: Larger TS was associated with a higher R1 rate and is a worse prognostic factor in patients with R-PDAC | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Yonamine, Naoto |e verfasserin |4 aut | |
| 700 | 1 | |a Fujinuma, Ibuki |e verfasserin |4 aut | |
| 700 | 1 | |a Tsunenari, Takazumi |e verfasserin |4 aut | |
| 700 | 1 | |a Takihata, Yasuhiro |e verfasserin |4 aut | |
| 700 | 1 | |a Hakoda, Hiroyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Nakazawa, Akiko |e verfasserin |4 aut | |
| 700 | 1 | |a Iwasaki, Toshimitsu |e verfasserin |4 aut | |
| 700 | 1 | |a Einama, Takahiro |e verfasserin |4 aut | |
| 700 | 1 | |a Togashi, Junichi |e verfasserin |4 aut | |
| 700 | 1 | |a Tsujimoto, Hironori |e verfasserin |4 aut | |
| 700 | 1 | |a Ueno, Hideki |e verfasserin |4 aut | |
| 700 | 1 | |a Beck, Yoshifumi |e verfasserin |4 aut | |
| 700 | 1 | |a Kishi, Yoji |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of surgical oncology |d 1995 |g 30(2023), 13 vom: 01. Dez., Seite 8621-8630 |w (DE-627)NLM074734997 |x 1534-4681 |7 nnns |
| 773 | 1 | 8 | |g volume:30 |g year:2023 |g number:13 |g day:01 |g month:12 |g pages:8621-8630 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1245/s10434-023-14219-3 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 30 |j 2023 |e 13 |b 01 |c 12 |h 8621-8630 | ||